Sangamo Therapeutics Inc (NASDAQ: SGMO)’s stock price has increased by 11.85 compared to its previous closing price of 0.38. However, the company has seen a 42.34% increase in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-10-26 that Sangamo (SGMO) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is It Worth Investing in Sangamo Therapeutics Inc (NASDAQ: SGMO) Right Now?

and a 36-month beta value of 0.95. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 4 as “hold,” and 0 as “sell.”

The average price predicted for Sangamo Therapeutics Inc (SGMO) by analysts is $2.79, which is $2.36 above the current market price. The public float for SGMO is 158.30M, and at present, short sellers hold a 7.32% of that float. On November 20, 2023, the average trading volume of SGMO was 2.06M shares.

SGMO’s Market Performance

The stock of Sangamo Therapeutics Inc (SGMO) has seen a 42.34% increase in the past week, with a -16.51% drop in the past month, and a -52.65% fall in the past quarter. The volatility ratio for the week is 14.03%, and the volatility levels for the past 30 days are at 14.06% for SGMO. The simple moving average for the past 20 days is -0.70% for SGMO’s stock, with a -68.15% simple moving average for the past 200 days.

Analysts’ Opinion of SGMO

Many brokerage firms have already submitted their reports for SGMO stocks, with RBC Capital Mkts repeating the rating for SGMO by listing it as a “Sector Perform.” The predicted price for SGMO in the upcoming period, according to RBC Capital Mkts is $2 based on the research report published on November 03, 2023 of the current year 2023.

SGMO Trading at -26.11% from the 50-Day Moving Average

After a stumble in the market that brought SGMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.55% of loss for the given period.

Volatility was left at 14.06%, however, over the last 30 days, the volatility rate increased by 14.03%, as shares sank -9.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.67% lower at present.

During the last 5 trading sessions, SGMO rose by +45.62%, which changed the moving average for the period of 200-days by -87.46% in comparison to the 20-day moving average, which settled at $0.4310. In addition, Sangamo Therapeutics Inc saw -86.30% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at SGMO starting from BIOGEN INC., who sale 6,000,000 shares at the price of $0.50 back on Sep 26. After this action, BIOGEN INC. now owns 17,652,466 shares of Sangamo Therapeutics Inc, valued at $3,000,000 using the latest closing price.

Stock Fundamentals for SGMO

Current profitability levels for the company are sitting at:

• -180.85 for the present operating margin
• +89.12 for the gross margin

The net margin for Sangamo Therapeutics Inc stands at -172.76. The total capital return value is set at -52.87, while invested capital returns managed to touch -51.05. Equity return is now at value -112.37, with -61.33 for asset returns.

Based on Sangamo Therapeutics Inc (SGMO), the company’s capital structure generated 14.61 points at debt to equity in total, while total debt to capital is 12.75. Total debt to assets is 7.66, with long-term debt to equity ratio resting at 13.22. Finally, the long-term debt to capital ratio is 11.53.

When we switch over and look at the enterprise to sales, we see a ratio of -0.83, with the company’s debt to enterprise value settled at 0.17. The receivables turnover for the company is 20.55 and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.69.

Conclusion

To sum up, Sangamo Therapeutics Inc (SGMO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.